Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
116.03
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
89
90
Next >
Nike, Merck, General Motors, And More: CNBC's 'Final Trades'
June 10, 2024
Liz Young of SoFi recommends Energy Select Sector SPDR Fund as her final trade on CNBC's Halftime Report. Jim Lebenthal of Cerity Partners picks General Motors, while Jason Snipe of Odyssey Capital...
Via
Benzinga
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
June 10, 2024
If approved, this would be the first combination vaccine based on mRNA technology to hit the market.
Via
Investor's Business Daily
Exposures
COVID-19
Why Moderna Stock Is a No-Brainer Buy Right Now
June 10, 2024
This messenger-RNA pioneer should be able to keep its rebound going.
Via
The Motley Fool
3 Reasons to Buy Moderna Stock
June 08, 2024
The biotech hasn't said its last word.
Via
The Motley Fool
Market Whales and Their Recent Bets on MRK Options
June 07, 2024
Via
Benzinga
2 Dividend Stocks Billionaires Are Buying: Should You?
June 07, 2024
That's not a bad crowd to follow when investing in stocks.
Via
The Motley Fool
Comparative Study: Merck & Co And Industry Competitors In Pharmaceuticals Industry
June 04, 2024
Via
Benzinga
Smart Money Is Betting Big In MRK Options
May 30, 2024
Via
Benzinga
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
June 06, 2024
These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside
Via
InvestorPlace
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Merck & Co., Inc.
Via
Business Wire
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
June 04, 2024
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co...
Via
Benzinga
Large Cap BIopharmaceuticals Overview
June 03, 2024
As a defensive play healthcare is weighted at about 12% of the S&P 500.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients
June 03, 2024
Moderna and Merck's Phase 2b study results for mRNA-4157 combined with Keytruda, showing improvements in recurrence-free and distant metastasis-free survival for high-risk melanoma patients. Phase 3...
Via
Benzinga
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage
June 03, 2024
Via
ACCESSWIRE
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
June 01, 2024
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in...
Via
Talk Markets
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
May 31, 2024
Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly...
Via
Benzinga
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
May 29, 2024
Surmodics stock hit a two-year high on its GPCR takeover, but Merck stock was little moved on its EyeBio deal.
Via
Investor's Business Daily
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
May 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Acquire EyeBio
May 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
May 29, 2024
It's time to take CytomX Therapeutics stock seriously as CytomX Therapeutics forges a crucial partnership with a pharmaceutical powerhouse.
Via
InvestorPlace
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence
May 29, 2024
Merck & Co is reportedly on the verge of acquiring EyeBio, an eye-drug company, for a sum of $1.3 billion. This acquisition is expected to significantly expand Merck's presence in the rapidly growing...
Via
Benzinga
Merck Announces Third-Quarter 2024 Dividend
May 28, 2024
From
Merck & Co., Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
May 28, 2024
Via
Benzinga
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Lung Cancer Study
May 28, 2024
Merck's KEYNOTE-522 trial shows Keytruda combined with chemotherapy significantly improves overall survival in high-risk early-stage triple-negative breast cancer patients compared to chemotherapy...
Via
Benzinga
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
May 28, 2024
From
Merck & Co., Inc.
Via
Business Wire
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
May 28, 2024
For those who appreciate value investing, MERCK & CO. INC. (NYSE:MRK) is a compelling option with its solid fundamentals.
Via
Chartmill
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
May 27, 2024
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.
Via
Benzinga
S&P 500 Plays And One Dow Jones Giant Lead Five Stocks Near Buy Points
May 25, 2024
These five names are showing relative strength.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
May 24, 2024
Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy with...
Via
Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
May 24, 2024
The company passed investors' bar for success in a study of a head-and-neck cancer treatment.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
89
90
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.